Vertical: V15 - Pharmaceuticals and Bio Technology

Notice Board -

   Horizontals

V15H1 Biotherapeutics/ Biosimilars

The Indian pharmaceutical industry was valued at $ 36 billion in FY‐19 and is one of the largest contributors to foreign exports. India is known as the “Global Pharmacy” and is well recognized as a manufacturer of economical, safe and efficacious therapeutic solutions. More recently, India is trying to emulate its success in pharmaceutical manufacturing in that of biotech therapeutics. The biopharmaceutical sector accounts for the largest share of the biotech industry with a share of 64% of total revenues. India is among the top 12 destinations for biotechnology in the world, with approximately 3% share in the global Biotechnology industry. It can be concluded that biotech manufacturing is likely to play a critical role in the recently launched “Make in India” initiative. However, owing to inherent complexity of biotherapeutics, the sector faces unique challenges in manufacturing, market acceptance as well as regulatory framework for both innovative molecules as well as copy biologics, a.k.a biosimilars. India being a global leader in the domain of generic manufacturing and export, aims to replicate its success in the biotherapeutic domain as well for which a sound understanding and a solution driven trajectory for the associated challenges needs to be charted. The discussions under this vertical aim to bring together the diaspora of global Indian domain leaders and focus their thought processes and vision towards creating a roadmap for the future of biotherapeutics in India


V15H2 Industrial Biotechnology

Biotechnology sector has immense growth potential to play a significant role as an innovative manufacturing hub which can contribute very substantially to Indian economy. India is one of the world’s top 12 destinations for biotechnology. During the last few decades, India has made spectacular advances in several areas of biotechnology such as vaccine production, transgenic technologies, plant biotechnology etc. In our pursuit for rapid advances in genetic manipulation technologies we have established globally comparable capabilities. However, we have not given adequate attention on consolidating and developing indigenous capability to cater to the needs of Indian industry. For many of our industries related to diagnostic, biomedical, research, textiles, pulp and paper, leather processing, food processing, biofuel production etc, we import several million worth of enzymes needed for these industries. COVID-19 pandemic has revealed how much we depend on imports for our health and diagnosis related needs. Indigenous production of antibiotics, amino acids and other biomolecules has also declined quite substantially. India and its diaspora have the intellectual capability to produce these enzymes and biomolecules indigenously, but need policy interventions to support Biotech industry to contribute in this domain which will reduce our dependence and import bill. For the industrial scale production of industrial enzymes, amino acids, antibiotics, pharmaceuticals, we need to focus on rapid improvement in fermentation technology including bioreactor design and bioprocess development. A few decades back India was at par with other leading countries in the domain of fermentation technologies. But, due to emphasis on imports indigenous capabilities have dwindled down and now restricted to only a few select groups


V15H3 : Infectious Diseases/ Disease biology

Infectious disease is the field of disorders caused by pathogenic microorganisms and it is continue to be the major cause of death world-wide. Nearly one third of the cases of death caused by infectious diseases are attributable to tuberculosis, AIDS, and malaria. In addition, new infectious diseases like Covid-19 are arising and proving themselves to have major effects on society. In order to address various issues and related concerns, this theme will be focusing on several R&D activities in the area of infectious diseases. The common discussion on single platform will be most relevant for the country


V15H4 Drug Discovery, Repurposing and Drug delivery

India was one of the first nations to develop a synthetic drug. In the post-independence era, Indian Research and Development organisations supported by Govt of India have developed processes for production of generic drugs. Challenges for the future are to give scientific base of these academic R&D Institutions to develop research and clinical capability to produce new drugs consistently based on advances in modern chemical and biological sciences. There are many laudable initiatives undertaken by various science departments of the government, such as CSIR, DST, DBT, ICMR and IITs, Biotechnology Industry Research Assistance Council/Biotechnology Industry Partnership Programme (BIRAC/BIPP) by DBT, Government of India, that aim to bridge the gaps in new drugs discovery. To cite as an example, twelve new drugs from different CSIR laboratories established across the country have got approved Drug Controller General of India (DCGI). Developing drugs against neglected diseases is a challenge, as the market size may be small in financial terms. CSIR, with global partnership attempted to create a global virtual platform where best researchers can collaborate and devise solutions for complexities associated with discovering drugs for neglected tropical diseases like tuberculosis, malaria, leishmaniasis, etc. Owing to complexity in discovering new chemical entities and also translate them into products into market is challenging, costing time and money. In this connection delivering of existing drugs employing nanotechnology plays an important role. Hence, it is important to bridge the gaps by understanding the associated challenges. In this pursuit, Govt. of India initiated this VAIBHAV to exchange dialogue with researchers across the globe and discuss the road map for fostering collaborative research in India under “SWASTH BHARAT” initiative and ultimately “MAKE in INDIA”. The discussions under this vertical aim to bring together the diaspora of global Indian domain leaders and focus their thought processes and vision towards creating a roadmap for the future of new drug discovery programs in India


Session Schedule

Horizontal

Session ID

Name

University/Organisation

Country

Biotherapeutics and Biosimilars

V15H1S1

Regulatory perspectives on Biosimilars

09-10-2020

19:00 - 22:00 IST

Anurag S. Rathore

Indian Institute of Technology, Delhi

India

Mansoor A. Khan

Texas A&M university

United States of America

S. Eswara Reddy

Central Drugs Standard Control Organisation (CDSCO)

India

Kavita Singh

Biotechnology Industry Research Assistance Council (BIRAC)

India

Arun Kumar B. Ramteke

Clinical Development Services Agency (CDSA)

India

Vishal K. Gupta

JSS Academy of Higher Education & Research

India

Debendra K. Sahoo

CSIR - Institute of Microbial Technology

India

Vinod P. Shah

Ex-US Food and Drug Administration

United States of America

Narendra Chirmule

Ex-Amgen

United States of America

Pallavi Trivedi

Global Regulatory Affairs, RAPS EU COUNCIL

United Kingdom

Janakiraman Subramanian

Saint Luke's Cancer Institute, Kansas City, MO.

United States of America

V15H1S2

Biosimilars

16-10-2020

19:00 - 22:00 IST

Anurag S. Rathore

Indian Institute of Technology, Delhi

India

Mansoor A Khan

Texas A&M university

United States of America

DhinakarKompala

University of Colorado

United States of America

Ravi Pratap Narayan Mishra

CSIR - Institute of Microbial Technology

India

MugdhaGadgil

National Chemical Laboratory (NCL)

India

G R Soni

Ex-NIB

India

Neel Sarovar Bhavesh

International Centre for Genetic Engineering and Biotechnology (ICGEB)

India

Ramakrishna V. Hosur

Tata Institute of Fundamental Research (TIFR)

India

Shishir Chundawat

Rutgers University

United States of America

Srinivas Sistla

Virginia commonwealth University

United States of America

Krishna Mallela

Skaggs School of Pharmacy and Pharmaceutical Science

United States of America

Prashant Mhaskar

McMaster University, Canada

Canada

Balaji Somasundaram

University of Queensland

Australia

V15H1S3

Affordability of biotherapeutic products

23-10-2020

19:00 - 22:00 IST

Anurag S. Rathore

Indian Institute of Technology, Delhi

India

DhinakarKompala

University of Colorado

United States of America

Annu Uppal

US, Pharmacoepia

United States of America

Varun Ramamohan

Indian Institute of Technology, Delhi

India

Mahesh J Kulkarni

National Chemical Laboratory (NCL)

India

Ratnesh Jain

Institute of Chemical Technology (ICT)

India

Santosh Noronha

Indian Institutes of Technology, Bombay

India

Govind Rao

Center for Advanced Sensor Technology, UMBC, USA

United States of America

Sanjoy Bhattacharya

Miller School of Medicine, University of Miami

United States of America

Raja Ghosh

McMaster University, Canada

Canada

AjoyVelayudhan

University College London

United Kingdom

Industrial Biotechnology

V15H2S2

AMR bacterial pathogens in India

17-10-2020

1630 - 2000 IST

Prof. S. Ramaswamy

Purdue University

United States of America

Dr. Ankur Mutreja

University of Cambridge

United Kingdom

Dr. Sourav Ghosh

Loughborough University

United Kingdom

Dr. Sumanth Gandra

Washington University School of Medicine in St. Louis

United States of America

Dr. Anil Koul

Global Public Health & Infectious Discovery Research, J&J

Europe

Prof. Dhruba K Chattoraj

National Cancer Institute

United States of America

Dr. Amit Singh

Indian Institute of Science, Bangalore

India

Dr. Manju Bala

National Centre for Disease Control

India

Dr Rama Chaudhry

All India Institute of Medical Sciences

India

Dr. Sayantan Banerjee

World Health Organization

India

Dr. Amit Ghosh

National Institute of Cholera and Enteric Diseases

India

Prof. Ramandeep Singh

NCR Biotech Science Cluster

India

 Diseases/ Disease biology

V15H3S1

COVID 19

16-10-2020

18:00-22:00 IST

SamitChattopadhayay

BITS Pilani Goa Campus

India

Dr DipyamanGanguly

CSIR-IICB

India

Dr Shilpak Chatterjee

CSIR-IICB

India

Dr Ganes C Sen

Lerner Research Institute, Cleveland, Ohio

United States of America

Subhash C Verma

University of Neveda

United States of America

Sailen Barik

Cleaveland State Univeristy

United States of America

Uttiya Basu

Columbia University

United States of America

Dr Shikhar Mehrotra

Medical University of South Carolina

United States of America

Dr BarsanjitMajumder

Cleveland State University

United States of America

Dr Debashis Mitra

National Centre for Cell Science (NCCS)

India

Arvind K Sahu

National Centre for Cell Science (NCCS)

India

DrAnurag Agarwal

Institute of Genomics and Integrative Biology (IGIB) CSIR

India

Dr. Shahid Jameel

Asoka University

India

Dr Satyajit Rath

Indian Institute of Science Education and Research (IISER), Pune

India

V15H3S2

TB, Malaria, Leishmaniasis

15-10-2020

18:00-22:00 IST

Dr Rajesh Gokhale

National Institute of Immunology (NII)

India

Dr Vinay K Nandicoori

National Institute of Immunology (NII)

India

Lalitha Ramakrishnan

University of Cambridge

United Kingdom

Dr. Rama Krishna Vankayalapati

University of Texas Health Science Center

United States of America

Dr Amit Singhal

Singapore Immunology Network (SIgN)

Singapore

Dr Padmini Salgame

NJMS, Rutgers University

United States of America

Dr Neeraj Dhar

Swiss Federal Institute of Technology in Lausanne

Switzerland

Dr.SamitChattopadhayay

BITS Pilani Goa Campus

India

Dr Amit Singh

Indian Institute of Science (IISc), Bengaluru

India

Dr Ashis Kumar Das

Department of Biological Sciences, BITS Pilani

India

Arnab Pain

King Abdulla University of Science & Technology

Saudi Arabia

Nirbhay Kumar

George Washington Uiversity

United States of America

Chetan Chitnis

Institute Pasteur

Paris France

V Udhaya Kumar

Scientist Atlanta USA

United States of America

Debopam Chakrabarti

University of Central Florida

United States of America

Saman Habib

CSIR-CDRI Lucknow

India

Pawan Malhotra

ICGEB, New Delhi

India

Ashwani Kumar

Vector Research Centre,Pondicherry

India

DhanpatKochar

S.P.Medical College, Bikaner

India

Amit P Sharma

ICMR-National Institute of Malaria Research (NIMR)

India

Dr Syamal Roy

National Institute of Pharmaceutical Education & Research, Kolkata

India

Abhay R Satoskar

The Ohio State University

United States of America

Dr. Hira L Nakashi

Division of Emerging & Transfusion Transmitted Diseases, FDA

United States of America

Dr. Pradeep Das

ICMR-Rajendra Memorial Research Institute of Medical Sciences

India

Dr.Suvendranath Bhattacharya

CSIR-Indian Institute of Chemical Biology

India

Dr.Hemanta K Majumder

CSIR-Indian Institute of Chemical Biology

India

Mitali Chatterjee

Institute of PG Medical Education & Research

India

Drug Discovery, Repurposing and Drug delivery

V15H4S1

Chemical Therapeutics

15-10-2020

17:00 - 20:00 IST

E. Premkumar Reddy

Icahn School of Medicine, Mount Sinai

USA

SUBHASH C. CHAUHAN

School of Medicine
University of Texas Rio Grande Valley (UTRGV)

USA

Lakshmi P Kotra

University of Toronto

Canada

Vibha Tandon

Special Center for Molecular Medicine, JNU, Delhi

India

Thota Ganesh

School of Medicine, Emory University

USA

Swaroop Vakkalanka

Incozen Therapeutics

India

P Jaisankar

CSIR-IICB

India

Abbas Raza

University of Minnesota

USA

K.V. SASHIDHARA

CSIR-CDRI

India

Prasad V. Bharatam

NIPER Mohali

India

Sai Balaji

CSIR-IICT

India

V15H4S2

Drug Delivery and Nanoformulations

19-10-2020

17:00 - 20:00 IST

PN Gupta

Indian Institute of Integrative Medicine (IIIM), Jammu

India

S. Narasimha Murthy

The University of Mississippi

United States of America

Abhay Pandit

National University of Ireland Galway

Ireland

Srinath Palakurthi

Texas A&M Irma Lerma Rangel College of Pharmacy

United States of America

Vivek Gupta

College of Pharmacy & Health Sciences St. John’s University

United States of America

O. P. Katare

Panjab University, Chandigarh

India

MNV Ravi Kumar

TEXas A&M Irma Lerma Rangel College of Pharmacy, College Station, US

India

NeeleshMehra

National Institute of Pharmaceutical Education and Research, Hyderabad

India

Kamal Dua

University of Technology Sydney, Australia

Australia

Vandana Patravale

Department of Pharmaceutical Sciences and Technology

India

Shubhni Saraf

School of Pharmacy, Babsaheb Bhimrao Ambedkar Central University, Lucknow

India

ParijatKanaujia

Institute Of Chemical And Engineering Sciences Limited (ICES)

Singapore

V15H4S3

Drug Repurposing

16-10-2020

17:00 - 20:00 IST

Dev Mukhopadhyay

Mayo Clinic

USA

Naibedya Chattopadhyay

CSIR-CDRI

India

DudduPurnanandSarma

 

USA

KATTESH V. KATTI

University of Missouri

USA

Sabyasachi Sanyal

CSIR-CDRI

India

Sanjay V. Malhotra

Oregon Health & Science University

USA

K Sreekumaran Nair

Mayo Clinic, Rochester, Minnesota

USA

T. Govindaraju

Bioorganic Chemistry Laboratory, JNCASR, Bangaluru

India

Sudeep Pushpakom

Molecular and Clinical Pharmacology, University of Liverpool

USA

Shantanu Chowdhury

IGIB, New Delhi

India

M.Sridhar Reddy

CSIR-IICT

India

Praveen P Nekkar Rao

University of Waterloo

Canada

V15H4S4

Affordable drugs

19-10-2020

17:00 - 20:00 IST

Aloke Dutta

Wayne State University

United States of America

Ganesh Thakur

Department of Pharmaceutical Sciences &Center for Drug Discovery

United States of AmericaUSA

Umesh R. Desai

School of Pharmacy, Verginia Commonwealth University

United States of America

Rahul Jain

NIPER, Mohali

India

Arindam Talukdar

IICB, Kolkatta

India

Muraleedharan

IIT Madras

India

Harinath Chakrapani

ISER Pune

India

Ch. Raji Reddy

IICT

India

Sanjay Batra

CDRI Lucknow

India

Chepuri V. Ramana

CSIR-NCL

India

Haridas B. Rode

IICT

India

V15H4S5

Drugs for Neglected Diseases

20-10-2020

17:00 - 20:00 IST

Ramaiah Muthyala

University of Minnesota

United States of America

Rajesh Gokhale

NII, Delhi

India

Baljinder Singh

College of Science, Northeastern University

United States of America

Hosahudya N. Gopi

IISER, Pune

India

Ramesh Chandra

Department of Chemistry, University of Delhi

India

Asit K Chakraborti

NIPER Mohali

India

Parvinder Pal Singh

IIIM Jammu

India

Hira Nakhasi

US Food and Drug Administration

United States of America

Shridhar Narayanan

Foundation for neglected disease research

India

Praveen P Nekkar Rao

University of Waterloo

Canada

Ramesh Ummanni

India

India